TY - JOUR
T1 - Effect of low-dose probucol therapy on LDL oxidation and the plasma lipoprotein profile in male volunteers
AU - Cristol, Louis S.
AU - Jialal, Ishwarlal
AU - Grundy, Scott M
N1 - Funding Information:
We are indebted to Marjorie Whelan for helping to coordinate the study, Kathy Schutt for measuring plasma lipid levels, Beverly Adams Huet for her statistical analysis, Dr. Gloria Lena Vega for her helpful advice in the preparation of lipoprotein samples, the nursing staff of the Dallas Veterans Affairs Medical Center for their contribution to this study and Marion Merrel Dow for the gift of probucol and placebo and the measurement of plasma probucol levels. This work was supported by the Veterans Affairs Grants HL-29252 and MO-IRR00633 (NIH), by the Bristol Meyers Squibb Mead Johnson Nutrition Research Grant, The Southwestern Medical Foundation and the American Heart Association (Texas Affiliate).
PY - 1992/11
Y1 - 1992/11
N2 - The effect of 4 months of low-dose probucol treatment (250 mg/day) on LDL oxidation and on plasma-HDL cholesterol was studied in a prospective, double-blinded, randomized, placebo-controlled trial involving 26 male volunteers. LDL samples isolated at baseline and at 4 months were subjected to in vitro tests of LDL oxidation, involving copper-catalyzed, time-course experiments. For the placebo group, LDL oxidation did not significantly change over the 4-month period. However, in the probucol group, LDL oxidation was significantly inhibited at 4 months, as evidenced by assays measuring conjugated diene formation, lipid peroxide production and altered electrophoretic mobility of oxidized LDL. In fact, in the probucol group the 'lag-phase' of oxidation was prolonged 2.7-fold. Neither probucol nor placebo had a significant effect on plasma HDL-cholesterol: in the probucol group HDL-cholesterol fell from 37.7 ± 7.4 mg/dl to 34.2 ± 8.3 mg/dl (percentage decrease -8.9), while in the placebo group plasma HDL-cholesterol levels were 42.4 ± 8.3 mg/dl and 40.9 ± 7.0 mg/dl at baseline and 4 months (percentage decrease -2.7). Therefore, a low dose of probucol (250 mg/day) given daily seems to afford protection against the oxidative modification of LDL, and does not appear to exert any substantial effect on the plasma lipoprotein profile.
AB - The effect of 4 months of low-dose probucol treatment (250 mg/day) on LDL oxidation and on plasma-HDL cholesterol was studied in a prospective, double-blinded, randomized, placebo-controlled trial involving 26 male volunteers. LDL samples isolated at baseline and at 4 months were subjected to in vitro tests of LDL oxidation, involving copper-catalyzed, time-course experiments. For the placebo group, LDL oxidation did not significantly change over the 4-month period. However, in the probucol group, LDL oxidation was significantly inhibited at 4 months, as evidenced by assays measuring conjugated diene formation, lipid peroxide production and altered electrophoretic mobility of oxidized LDL. In fact, in the probucol group the 'lag-phase' of oxidation was prolonged 2.7-fold. Neither probucol nor placebo had a significant effect on plasma HDL-cholesterol: in the probucol group HDL-cholesterol fell from 37.7 ± 7.4 mg/dl to 34.2 ± 8.3 mg/dl (percentage decrease -8.9), while in the placebo group plasma HDL-cholesterol levels were 42.4 ± 8.3 mg/dl and 40.9 ± 7.0 mg/dl at baseline and 4 months (percentage decrease -2.7). Therefore, a low dose of probucol (250 mg/day) given daily seems to afford protection against the oxidative modification of LDL, and does not appear to exert any substantial effect on the plasma lipoprotein profile.
UR - http://www.scopus.com/inward/record.url?scp=0026441110&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0026441110&partnerID=8YFLogxK
U2 - 10.1016/0021-9150(92)90046-J
DO - 10.1016/0021-9150(92)90046-J
M3 - Article
C2 - 1445490
AN - SCOPUS:0026441110
SN - 0021-9150
VL - 97
SP - 11
EP - 20
JO - Atherosclerosis
JF - Atherosclerosis
IS - 1
ER -